To elucidate whether the activation of the eIF2α-ATF4 pathway per se was sufficient for the increases in xCT expression and cisplatin resistance, we treated the cancer cells with salubrinal (an eIF2α phosphatase inhibitor) [23] to elevate the activity of this pathway. The gene discussed is ATF4; the disease is cancer.